Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05764720 · ClinicalTrials.gov registry record · NA
Stereotactic Adaptive Radiation Therapy of Borderline Resectable Pancreatic Cancer an Individualized Approach
A NA study of Pancreatic Cancer, sponsored by Varian, a Siemens Healthineers Company.
- Recruiting
- Registry status
- NA
- Development phase
- 134
- Enrollment target
- 3
- Study locations
NCT05764720 is a NA study of Pancreatic Cancer that is actively recruiting participants, run by Varian, a Siemens Healthineers Company. The registered enrollment target is 134 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (66% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT05764720, a NA study of Pancreatic Cancer, is actively recruiting participants, sponsored by Varian, a Siemens Healthineers Company.
- RECRUITING
- Registry status
- NA
- Development phase
- 134 participants
- Enrollment target
- 3
- Study locations
Study Summary
This trial is a single-arm, prospective, multi-center clinical trial designed to demonstrate that stereotactic adaptive radiotherapy using an ablatively dosed (50Gy,5fx) for treatment of borderline-resectable, locally-advanced , or medically inoperable pancreatic adenocarcinoma will translate into a decreased toxicity. The study will evaluate GI toxicity, overall survival, local control, quality of life, and workflow metrics.
Conditions Studied
Interventions
- RADIATION Daily Adaptive External Beam Radiation Therapy
Study Locations (3)
Alabama
- University of Alabama at Birmingham - Birmingham
Missouri
- Washington University, St. Louis - St Louis
Ohio
- UH Cleveland Medical Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2023-05-14 |
| Est. Completion | 2030-03-15 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05764720
The ClinicalTrials.gov registry entry for NCT05764720 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 134 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (66% lower). The listed sponsor is Varian, a Siemens Healthineers Company, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which Daily Adaptive External Beam Radiation Therapy is the first listed.
NCT05764720 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Alabama, Missouri, Ohio.
Frequently Asked Questions
What is clinical trial NCT05764720 about?
NCT05764720 is a clinical study titled "Stereotactic Adaptive Radiation Therapy of Borderline Resectable Pancreatic Cancer an Individualized Approach". This trial is a single-arm, prospective, multi-center clinical trial designed to demonstrate that stereotactic adaptive radiotherapy using an ablatively dosed (50Gy,5fx) for treatment of borderline-resectable, locally-advanced , or medically inoperable pancreatic adenocarcinoma will translate into a...
What is the current status of trial NCT05764720?
This trial is currently recruiting. It is a NA study. The enrollment target is 134 participants. The study started on 2023-05-14. Estimated completion is 2030-03-15.
What conditions does trial NCT05764720 study?
This clinical trial studies the following conditions: Pancreatic Cancer.
What interventions are being tested in trial NCT05764720?
The interventions under investigation include: Daily Adaptive External Beam Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT05764720?
This trial is sponsored by Varian, a Siemens Healthineers Company, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05764720 being conducted?
This trial has 3 study locations across Alabama, Missouri, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
RECRUITING · NA
-
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
RECRUITING · NA
-
EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope
RECRUITING · NA
-
Computed Tomography in Diagnosing Patients With Pancreatic or Hepatobiliary Cancer
RECRUITING · NA
-
Support Through Remote Observation and Nutrition Guidance Program (STRONG-PCS)
RECRUITING · NA
-
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.